MLTX

MoonLake Immunotherapeutics Class A Ordinary Shares

12.39

USD

+0.04

+0.32%

Sep 18, 15:59 UTC -4

Closed

After-Market

12.37

-0.03

-0.20%

MLTX Earnings Reports

Positive Surprise Ratio

MLTX beat 10 of 17 last estimates.

59%

Next Report

Date of Next Report

Nov 03, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.79

Implied change from Q2 26 (Revenue/ EPS)

-5.95%

Implied change from Q3 25 (Revenue/ EPS)

-28.18%

MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue

On Aug 10, 2026, MLTX reported earnings of -0.84 USD per share (EPS) for Q2 26, beating the estimate of -0.93 USD, resulting in a 10.35% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.73% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.79 USD, with revenue projected to reach -- USD, implying an decrease of -5.95% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

enGene Therapeutics Inc. Common Stock

Report Date

Sep 08, 2026 For Q3 26

Estimate

-$0.43

Actual

-$0.47

Surprise

-7.16%

Anixa Biosciences, Inc.

Report Date

Sep 09, 2026 For Q3 26

Estimate

-$0.08

Actual

-$0.08

Surprise

+8.78%

Alzamend Neuro, Inc. Common Stock

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.57

Actual

-$0.68

Surprise

-19.05%

FAQ

What were MoonLake Immunotherapeutics Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$0.84, beating estimates by 10.35%, and revenue of $0.00, 0% as expectations.

How did the market react to MoonLake Immunotherapeutics Class A Ordinary Shares's Q2 2026 earnings?

The stock price moved up 2.73%, changed from $17.55 before the earnings release to $18.03 the day after.

When is MoonLake Immunotherapeutics Class A Ordinary Shares expected to report next?

The next earning report is scheduled for Nov 03, 2026.

What are the forecasts for MoonLake Immunotherapeutics Class A Ordinary Shares's next earnings report?

Based on 11 analysts, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$0.79 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.